Physician profile
Paul A Kovach
NPI 1194733279
$2,934.32
in general payments reported to CMS, 2019-2025
17 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $34.96 · 2021: $321 · 2022: $502 · 2023: $281 · 2024: $1,287 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086 · Travel and Lodging: $694 · Education: $51.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,086.44 |
| Travel and Lodging | $694.21 |
| Education | $51.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $1,125.86 | 2023-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $369.37 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $215.54 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $180.07 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.13 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $123.32 | 2023 | |
| Novo Nordisk INC | $121.84 | 2025 | Ozempic |
| Calliditas Therapeutics US INC. | $113.96 | 2024 | |
| Glaxosmithkline, LLC. | $106.55 | 2023 | Jesduvroq |
| Pharmacosmos Therapeutics INC. | $101.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $89.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $72.34 | 2024-2025 | |
| Akebia Therapeutics INC | $71.79 | 2024-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $41.22 | 2020-2021 | |
| Amgen INC. | $23.80 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $18.33 | 2019 | |
| Nxstage Medical, INC. | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kovach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.